ProCE Banner Activity

A New Chapter in ART? Implications of ATLAS and FLAIR Results From CROI 2019

Conference Coverage
Clinical Thought
Among the most noteworthy data presented at CROI 2019 were results from the phase III ATLAS and FLAIR studies of long-acting injectable cabotegravir plus rilpivirine. Here’s my take on how this regimen, if approved, could benefit people living with HIV.

Released: May 10, 2019

Expiration: May 08, 2020

No longer available for credit.

Share

Faculty

W. David Hardy

W. David Hardy, MD

Clinical Professor of Medicine
David Geffen School of Medicine at UCLA
Los Angeles, California

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

This program is supported by independent educational grants from

Gilead Text

Janssen

Merck Human Health HIV

ViiV Healthcare

Faculty Disclosure

Primary Author

W. David Hardy, MD

Clinical Professor of Medicine
David Geffen School of Medicine at UCLA
Los Angeles, California

W. David Hardy, MD, has disclosed that he has received funds for research support from Gilead Sciences, Janssen, Merck, and ViiV Healthcare and consulting fees from Gilead Sciences, Merck, and ViiV Healthcare.